Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji Kumar, Philippe Moreau, Kenshi Suzuki et al.|The Lancet Oncology|2020Cited by 401
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Asher Chanan‐Khan et al.|Blood|2017Cited by 271
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapyRelja Popovic, Brenda Chyla, Fengjiao Dunbar et al.|American Journal of Hematology|2021Cited by 19